Stock comparison
Catalyst Pharmaceuticals
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CPRX
Catalyst Pharmaceuticals
Market cap
$3.83B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
Catalyst Pharmaceuticals CPRX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CPRX | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 69C | 71B | UTHR |
| Benjamin Graham | 75B | 76B | UTHR |
| Philip Fisher | 87C | 76B | CPRX |
| Peter Lynch | 65B | 62C | CPRX |
| Joel Greenblatt | 42D | 46D | UTHR |
| Charlie Munger | 78B | 64C | CPRX |
| Terry Smith | 78B | 64C | CPRX |
Side-by-side metrics
| Metric | CPRX | UTHR |
|---|---|---|
| Market cap | $3.83B | $24.13B |
| P/E (TTM) | 17.3x | 19.2x |
| EV/EBIT | 11.9x | 15.2x |
| ROIC (TTM) | 19.67% | 18.81% |
| Gross margin | 82.32% | 86.58% |
| Net margin | 37.08% | 40.61% |
| Revenue CAGR 5y | 43.0% | 17.22% |
| EPS CAGR 5y | 46.49% | 29.84% |
| Debt / Equity | 0.0x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CPRX leads on
- Revenue CAGR 5y43.0%vs 17.22%+60%
- EPS CAGR 5y46.49%vs 29.84%+36%
- EV/EBIT11.9xvs 15.2x+22%
- P/E (TTM)17.3xvs 19.2x+10%
UTHR leads on
- Debt / Equity-vs 0.0x+100%
- Market cap$24.13Bvs $3.83B+84%
- Net margin40.61%vs 37.08%+9%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.